August 2018

New Product - Juluca

Dolutegravir (sodium)/rilpivirine (hydrochloride) (Juluca) contains two human immunodeficiency virus (HIV) antivirals, dolutegravir (HIV integrase inhibitor) and rilpivirine (non-competitive, diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI)). Juluca is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or integrase inhibitor. Juluca therapy should be initiated by a physician experienced in the management of HIV infection. Juluca is contraindicated in combination with the following: antiarrhythmic agent dofetilide; anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin; antimycobacterials rifampicin, rifapentine; proton pump inhibitors (such as omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole); glucocorticoid systemic dexamethasone (except as a single dose treatment); St John’s wort (Hypericum perforatum). Juluca fixed dose combination tablets containing dolutegravir 50 mg (as dolutegravir sodium) and rilpivirine 25 mg (as rilpivirine hydrochloride) are available in packs of 30.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629